Department II of the Center for Liver Diseases is affiliated with Beijing Ditan Hospital, Capital Medical University, and the National Center for Infectious Diseases. It is recognized as a Peak Team by the Beijing Municipal Medical Administration Center and a Leading Discipline Team for High-Level Health Technical Talents in Hepatology by the Beijing Municipal Health Commission. The department serves as the principal unit of the Capital Medical University Joint Laboratory for HBV Infection, Clinical Cure, and Immunity, as well as the main unit of the Hepatology Teaching and Research Division.

It is also a doctoral and master's student training site and postdoctoral collaboration team under Peking University Health Science Center and Capital Medical University, in addition to being an undergraduate clinical teaching base. Furthermore, it serves as a standardized training base for second-stage resident physicians in internal medicine (infectious diseases specialty) under the Health Commission, a medical-prevention integration training base, and a national training base for hepatology physicians.

As a key discipline integrating medical excellence, research strength, and educational resources, the department is a renowned clinical and research unit in hepatology both in Beijing and nationally. The team specializes in diagnosing and treating various liver diseases and their complications caused by different etiologies. Its clinical focus includes achieving clinical cure for chronic hepatitis B, antiviral treatment for chronic hepatitis B and C cirrhosis, management of liver cirrhosis and its complications, comprehensive rescue therapy for severe hepatitis, systematic treatment for liver cancer patients, and diagnosis and treatment of complex and unexplained liver diseases. The department operates specialist and premium outpatient clinics, as well as inpatient services.

With a robust academic primarily composed of master's and doctoral graduates, the team excels in integrating medical practice, teaching, and research. It has consistently dedicated efforts to both clinical and fundamental research in hepatology. In recent years, the team has led over 40 research projects, including those funded by the National Natural Science Foundation, National Key R&D Programs, and major sub-projects under the 11th, 12th, and 13th Five-Year Plans. It has also spearheaded more than 10 international/national multicenter clinical trials for liver disease drugs and presided over or participated in over 60 international or domestic multicenter clinical trials for liver disease-related drugs/medical devices. These efforts have contributed to the successful registration and market launch of more than 20 hepatology-related pharmaceuticals, reagents, and medical devices.

The team's project, "Establishment and Application of Innovative Technologies for the Prevention, Diagnosis, and Treatment of Chronic Hepatitis B," was awarded the Second Prize of the Beijing Science and Technology Progress Award in 2021, the Second Prize of the Capital Medical University Science and Technology Progress Award in 2022, and the Clinical Medical Research Innovation Award at the 8th Wuzhou Women in Science Awards in 2023.